Freeline Therapeutics Holdings plc financial data

Symbol
FRLN on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
Sycamore House, Gunnels Wood Road, Stevenage, Hertfordshire, United Kingdom
State of incorporation
United Kingdom
Fiscal year end
December 31
Former names
Freeline Therapeutics Holdings Ltd (to 7/10/2020)
Latest financial report
Q1 2023 - May 30, 2023

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 235 % -47.2%
Debt-to-equity 55.1 % +8.19%
Return On Equity -108 % -30.6%
Return On Assets -65.3 % +13%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 65.1M shares +81.6%
Common Stock, Shares, Outstanding 65.4M shares +0.61%
Weighted Average Number of Shares Outstanding, Basic 65.1M shares +52.7%
Weighted Average Number of Shares Outstanding, Diluted 65.8M shares +54.2%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 10.9M USD -45.4%
General and Administrative Expense 8.05M USD -2.08%
Operating Income (Loss) -20.1M USD +28.7%
Nonoperating Income (Expense) 21.4M USD +1366%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 1.33M USD
Income Tax Expense (Benefit) 162K USD +636%
Net Income (Loss) Attributable to Parent 1.17M USD
Earnings Per Share, Basic 0.02 USD/shares
Earnings Per Share, Diluted 0.02 USD/shares

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 29.5M USD -55.3%
Other Assets, Current 953K USD -23.6%
Assets, Current 34M USD -54.1%
Property, Plant and Equipment, Net 8.63M USD -20%
Operating Lease, Right-of-Use Asset 3.93M USD -66.5%
Intangible Assets, Net (Excluding Goodwill) 3K USD -70%
Other Assets, Noncurrent 2.67M USD -23.3%
Assets 49.2M USD -50.8%
Accounts Payable, Current 7.78M USD -21.9%
Employee-related Liabilities, Current 2.74M USD -31.3%
Liabilities, Current 17.5M USD -22%
Operating Lease, Liability, Noncurrent 1.7M USD -81.2%
Liabilities 19.2M USD -39.1%
Accumulated Other Comprehensive Income (Loss), Net of Tax -1.57M USD +82.3%
Retained Earnings (Accumulated Deficit) -472M USD -11.8%
Stockholders' Equity Attributable to Parent 30M USD -56.2%
Liabilities and Equity 49.2M USD -50.8%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -18.4M USD +30.6%
Net Cash Provided by (Used in) Financing Activities 27.5M USD
Net Cash Provided by (Used in) Investing Activities 23.8M USD
Common Stock, Shares Authorized 400M shares 0%
Common Stock, Shares, Issued 65.4M shares +0.61%
Common Stock, Par or Stated Value Per Share 0 GBP/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 6.51M USD
Deferred Tax Assets, Valuation Allowance 80.4M USD +17.2%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.19 pure 0%
Deferred Tax Assets, Gross 80.9M USD +17.3%
Operating Lease, Liability 3.99M USD -66.7%
Payments to Acquire Property, Plant, and Equipment 392K USD -25.5%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent 2.44M USD
Lessee, Operating Lease, Liability, to be Paid 4.34M USD -74.2%
Property, Plant and Equipment, Gross 14.7M USD -14%
Operating Lease, Liability, Current 2.29M USD -20.7%
Lessee, Operating Lease, Liability, to be Paid, Year Two 675K USD -74.5%
Lessee, Operating Lease, Liability, to be Paid, Year One 1.94M USD -45.8%
Operating Lease, Weighted Average Discount Rate, Percent 0.11 pure +54.9%
Deferred Income Tax Expense (Benefit) -156K USD +8.77%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 383K USD -92.8%
Lessee, Operating Lease, Liability, to be Paid, Year Three 654K USD -54.6%
Deferred Tax Assets, Operating Loss Carryforwards 78.1M USD +21%
Current Income Tax Expense (Benefit) 524K USD +2.14%
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 326K USD -73.5%
Operating Lease, Payments 765K USD -75.8%
Additional Paid in Capital 504M USD +0.82%
Depreciation, Depletion and Amortization 320K USD -40.9%
Deferred Tax Assets, Net of Valuation Allowance 535K USD +41.9%
Share-based Payment Arrangement, Expense 973K USD -29.3%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%